Video

Dr. Valderrabano on Understanding Cancer Risk in Indeterminate Thyroid Nodules

Pablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.

Pablo Valderrabano, MD, clinical research fellow, Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.

Thyroid nodules, solid or fluid-filled lumps within the thyroid gland, are common. While only around 1 in 10 of these are diagnosed as cancer, 20% to 30% of nodules cannot be adequately characterized by currently available tests and are classified as indeterminate. Most nodules classified as indeterminate require surgical intervention to make a diagnosis, says Valderrabano.

To determine if all indeterminate nodules require the same treatment, researchers at Moffitt Cancer Center looked at 271 nodules classified as indeterminate and categorized them into four groups: nuclear atypia nodules, nodules composed of follicular cells, nodules composed of hurthle cells, and other types of nodules. Upon investigation of each group it was determined that nuclear atypia nodules had a much higher prevalence of malignancy than any other nodules, with 62% of nodules testing positive for cancer.

<<<

View more from the 2015 International Thyroid Congress

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center